Stellar trial rosuvastatin. In the STELLAR trial, CRESTOR increased HDL-C at each dose.

Stellar trial rosuvastatin org december 1, 2011 2079 R andomized clinical trials have consistently shown that inhibitors of ^ Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Nicholls SJ, et al. 22–24,27,41 The effect of statins on clinical outcomes is modeled based Feb 11, 2014 · The STELLAR trial, 13,15,18 MERCURY trial, 7,19 and PULSAR 19 are the major open-label, randomized, multicenter trials to compare rosuvastatin (10, 20, 40, or 80 mg) with atorvastatin (10, 20, 40, or 80 mg), pravastatin (10, 20, or 40 mg), and simvastatin (10, 20, 40, or 80 mg) across dose ranges for reduction of LDL-C. Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The results of the STELLAR trial revealed that rosuvastatin was consistently, across all doses, the most effective at reducing LDL-C levels in comparison to all of the other statins. 8, 36. Get ideas for your own presentations. Curr Med Res Opin . This means that those at increased risk of cardiovascular complications due to high cholesterol now have access to a fourth funded HMG-CoA reductase inhibitor, or statin. METHODS: The cost-effectiveness of cholesterol-lowering therapy with rosuvastatin compared to atorvastatin, simvastatin, and pravastatin was estimated with a Markov model of cardiovascular Feb 1, 2024 · The Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial reported 6-week change in LDL level of –45. Design: A retrospective pharmacoeconomic analysis was performed using data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. Dec 1, 2011 · Jones, PH, Davidson, MH, Stein, EA, et al. 4 To date, the worldwide clinical development of rosuvastatin is the largest and most comprehensive programme to assess the efficacy and safety of a new statin. In the first simulated trial, treatment with rosuvastatin was estimated to result in greater reductions than treatment with atorvastatin in major adverse cardiac event (MACE) rates at 5 years and 20 years at all doses examined (relative risk [RR]: 0. 074. 359 no. Cost effectiveness of rosuvastatin in treating patients to low density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US analysis of the stellar trial) Am J Cardiol. In an attempt to reduce potentially missed opportunities for instituting preventive therapy, the JUPITER study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) and the AURORA study (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Oct 25, 2019 · An open-label Phase III trial (STELLAR*TRIAL) then followed between April 2001 and March 2002 (Jones et al. to Rosuvastatin (STELLAR) trial examines the effects of statin therapy in hypercholesterolemic women. 1016/J. 92% for rosuvastatin and –38. 002 Citation 21), and this larger TC/HDL reduction translates directly to a greater reduction in MI risk as predicted by the Archimedes Model. 15 The results of the rosuvastatin across its dose range. Sep 1, 2004 · DOI: 10. 8% to 9. American Journal of Cardiology. Two real-world studies found that rosuvastatin use was associated with a 28-40% lower risk of cardiovascular events compared to other statins. Therefore, reducing LDL cholesterol (LDL-C) to the goals recommended by clinical practice guidelines, is essential to decrease the risk of vascular complications. 001) than simvastsatin and pravastatin. It was a randomized, double-blind, placebo-controlled trial conducted on adults with hypercholesterolemia. Am J Cardiol 2003 The Saturn study aimed to evaluate the effectiveness of Rosuvastatin in reducing LDL cholesterol levels and preventing cardiovascular events. 074 Corpus ID: 31007638; Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). +9. Rosuvastatin at 10 mg, the recommended starting dose, was the most cost-effec-tive statin over a large range of “willingness-to-pay” Feb 13, 2024 · Vascular diseases are the leading cause of death in Spain. 8% with rosuvastatin 10 mg and –36. Conclusion In summary, 10 mg of rosuvastatin tablet was comparable to 10 mg of atorvastatin tablet and more efficacious than 10 mg tablet simvastatin in reducing LDL levels after 12 Jan 1, 2010 · Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial Jan 1, 2003 · SUMMARY In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor*) was compared with that of atorvastatin (Lipitor †), simvastatin (Zocor‡), and pravastatin (Pravachol§) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks Apr 18, 2013 · Citation 1, Citation 6, Citation 27 The Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) study, which was a 6-week, parallel-group, open-label, randomized, multicenter trial in over 2400 patients with hypercholesterolemia, compared the lipid-lowering effect of rosuvastatin with other commonly used statins. Confidential data analysis will be supplied to an independent Data Monitoring Committee (DMC), operating in line with a trial specific charter. Jul 15, 2003 · The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. Least-squares mean (SE) percentage changes from baseline in LDL cholesterol at week 6, and mean differences (SE) across the dose ranges from the analysis of covariance (versus atorvastatin and pravastatin) and analysis of variance (versus simvastatin) for (A) rosuvastatin versus atorvastatin (95% confidence interval 6. May 18, 2015 · To perform these virtual clinical trials, the core Archimedes model was expanded to include data on rosuvastatin 20 mg/d and 40 mg/d doses from the JUPITER and STELLAR trials, and data on atorvastatin 40 mg/d and 80 mg/d from the CARDS, ASCOT-LLA, STELLAR, and TNT trials. 002 vs pravastatin 10 mg). Feb 1, 2005 · Mark Hirsch, John C O'donnell, Peter Jones, Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin, Pravastatin and Simvastatin: Analysis of the Stellar Trial, European journal of cardiovascular prevention and rehabilitation, Volume 12, Issue 1, 1 February 2005, Pages 18–28 The Stellar Trial Rosuvastatin is a comprehensive research study conducted by a team of medical experts and researchers. BACKGROUND Rosuvastatin calcium (CRESTOR) has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C). 1016/j. 7,8 Data also suggested dose-dependent effects of atorvastatin and rosuvastatin on insulin levels. 2003;92:152-16012860216Google Scholar Crossref Apr 2, 2009 · Patients in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (NCT00206310) 30 and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca Heart These results are consistent with the STELLAR trial where rosuvastatin, atorvastatin, and simvastatin reduced LDL levels by 45. 8, and 28. Rosuvastatin appears to be the most potent of the available statins, leading to both the greatest LDL-C lowering and HDL-C raising effects in the MERCURY I and II trials Citation 12, Citation 13 and the STELLAR trial. ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. Mar 1, 2005 · Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: Analysis of the STELLAR trial In patients with hypercholesterolaemia, rosuvastatin is a cost-effective statin option in treating to LDL-C goals and Sensitivity analyses showed that the results were robust to variations in both statln efficacy and price. BackgroundRosuvastatin calcium (CRESTOR®) has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C). Am J Cardiol. Mar 16, 2007 · Abstract. This trial compared rosuvastatin with atorvastatin, simvastatin, and pravastatin. 930 at 5 years for rosuvastatin 20 mg vs atorvastatin 40 mg, rosuvastatin 40 mg vs atorvastatin 80 mg, and Feb 11, 2014 · The STELLAR trial, 13,15,18 MERCURY trial, 7,19 and PULSAR 19 are the major open-label, randomized, multicenter trials to compare rosuvastatin (10, 20, 40, or 80 mg) with atorvastatin (10, 20, 40, or 80 mg), pravastatin (10, 20, or 40 mg), and simvastatin (10, 20, 40, or 80 mg) across dose ranges for reduction of LDL-C. The clinical trial programme consisted of 33 phase I and 27 phase II/III clinical trials and included more than 12 500 rosuva-statin-treated patients PSJ M, DG S, P J. ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP investigational drug trial within 4 weeks of trial enrollment. , Cressman M. In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor ), simvastatin (Zocor), and pravastatin (Pravachol) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of treatment. The lowering of triglycerides is another important goal in reducing CVD risk among diabetic patients . However, healthcare providers and Mar 1, 2007 · The Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial was a 6-week trial that compared the effects of the newer statin rosuvastatin with atorvastatin, pravastatin, and simvastatin in hypercholesterolemic patients. Brand and generic drug costs were POLARIS investigated the efficacy and safety of rosuvastatin 40 mg and atorvastatin 80 mg in high-risk patients with hypercholesterolemia. 21 Rosuvastatin to Prevent Vascular Events in Men and Feb 10, 2013 · Our results are consistent with STELLAR trial which is one of the major open-label, randomized, and multicenter trials to compare rosuvastatin (10, 20, 40, or 80 mg) with atorvastatin (10, 20, 40, or 80 mg), pravastatin (10, 20, or 40 mg), and simvastatin (10, 20, 40, or 80 mg) across dose ranges for reduction of LDL-C . 19 This subgroup analysis examines the Mar 6, 2023 · In the STELLAR trial, the addition of 24-week treatment with sotatercept to background therapy with currently available medications improved exercise capacity as assessed by 6-minute walk distance The majority of rosuvastatin's clinical trials are comparator-controlled studies between rosuvastatin and pravastatin, simvastatin, or atorvastatin. 07% for This superiority of rosuvastatin is in keeping with the findings of several other trials done on other racial groups. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Nov 1, 2006 · Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. METEOR was a randomized, double-blind, placebo-controlled trial comparing the effect of CRESTOR 40 mg with placebo on the progression of atherosclerosis over 2 years in 984 low-risk patients (defined as Framingham risk score of <10% over 10 years) with hypercholesterolemia (mean LDL-C of 155 mg/dL) and subclinical atherosclerosis as detected by CIMT for 12 Feb 1, 2005 · Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin, Pravastatin and Simvastatin: Analysis of the Stellar Trial Feb 1, 2008 · The Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial was a 6-week trial that compared the effects of the newer statin, rosuvastatin, with atorvastatin, pravastatin, and simvastatin in hypercholesterolemic patients. 19 This subgroup analysis examines the Jun 1, 2005 · In a 6-week, parallel-group, open-label, multicenter, randomized trial (Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin [STELLAR]), the effects of rosuvastatin (10, 20, or 40 mg) on low-density lipoprotein (LDL) cholesterol levels were compared with those of atorvastatin (10, 20, 40, or 80 mg), pravastatin (10, 20, or 40 mg), and simvastatin (10, 20, 40, or 80 In patients with hypercholesterolaemia, rosuvastatin is a cost-effective statin option in treating to LDL-C goals and Sensitivity analyses showed that the results were robust to variations in both statin efficacy and price. 09. 9 years (maximum, 5. AMJCARD. To determine which statin will better improve the apolipoprotein (Apo) profiles (ApoA-I levels, ApoB levels, and ApoB/A-I ratios), we performed a meta-analysis of randomized head-to-head trials of rosuvastatin versus atorvastatin therapy. Chicago, IL most potent statins (rosuvastatin versus atorvastatin) in patients with CAD. +7. Large scale clinical trials demonstrated worsening of insulin and glycated hemoglobin (HbA1c) with atorvastatin and rosuvastatin treatment. Sep 1, 2004 · The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C >-160 mg/dL and <250 mg/dL and triglycerides <400 Dec 29, 2024 · The study I know the most about, which my colleagues and I published in the summer of 2003 in the American Journal of Cardiology, was the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial. Specifically, rosuvastatin 10 mg lowered LDL-C more than atorvastatin Ridker PM, MacFadyen J, Cressman M, et al. STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. Notable amongst these is the landmark statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR) trial done on 2431 patients comparing rosuvastatin with atorvastatin, simvastatin, and pravastatin The Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial (clinicaltrials. PubMed ID Jan 15, 2006 · This trial compared the efficacy and safety of rosuvastatin and atorvastatin during 6 weeks of treatment in hypercholesterolemic African-American adults. Participants 4400 adults (age ≥19 years) with coronary artery disease. 22 – 24, 27, 41 The effect of statins on clinical outcomes is modeled n engl j med 359;21 www. [Google Scholar] Moon JC, Bogle RG. 2005;95:1314–1319. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C ‡160 and <250mg/dL) and triglycerides <400mg/dL were randomized to rosuvastatin 10–40mg, atorvastatin Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin, Pravastatin and Simvastatin: Analysis of the Stellar Trial Mark Hirsch , BSc [email protected] , John C. Interventions Participants were assigned to receive either Jul 15, 2003 · Body mass index (BMI) (killograms per square meter) was not calculated for the following numbers of patients: 4 in the rosuvastatin 10- to 40-mg group, 9 in the rosuvastatin 10- to 80-mg group, 6 in the atorvastatin 10- to 80-mg group, 3 in the simvastatin 10- to 80-mg group, and 2 in the pravastatin 10- to 40-mg group. 7% with CRESTOR 10 mg (P value is less than . Doses to Rosuvastatin (STELLAR) trial. The STELLAR study showed that rosuvastatin more effectively lowered LDL-C and raised HDL-C than other statins. The study included 9,438 patients who were randomly assigned to receive either Rosuvastatin or Despite guidelines recommending the use of statin treatment in hypercholesterolemic women, this patient group is often undertreated. Jul 1, 2005 · Clinical data were obtained from the STELLAR trial (n=2268) in which patients received fixed doses of rosuvastatin, atorvastatin, simvastatin and pravastatin. Abstract FIGURE 3. org november 20, 2008 2195 The new england journal of medicine established in 1812 november 20, 2008 vol. Cost effectiveness was assessed with the net monetary benefit approach and a 1-year time horizon. , Glynn R. 8% with atorvastatin 10 mg. Design Randomised, open label, multicentre trial. Mar 30, 2014 · This superiority of rosuvastatin is in keeping with the findings of several other trials done on other racial groups. Jun 1, 2005 · DOI: 10. 22 – 24, 27, 41 The effect of statins on clinical outcomes is modeled Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. The relevant institutional review boards approved the trial protocol and any amendments, and the trial was performed in accor-dance with the ethical principles consistent with good clinical practice. The Stellar Study utilizes a rigorous research design to ensure reliable results. Jul 15, 2003 · The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. 1 This was a 6-week, parallel-group, open-label, multicenter trial that enrolled men and women who were ≥18 years of age and had hypercholesterolemia (LDL cholesterol concentrations ≥160 mg/dl and <250 mg/dl; triglyceride concentration <400 mg/dl). Patients (n=871) were randomized to rosuvastatin 40 mg/day or atorvastatin 80 mg/day for 26 weeks. doi: 10. 18,21 Meta-analysis of non-diabetic subjects from 16 randomized controlled trial showed that pravastatin Nov 27, 2015 · To perform these virtual clinical trials, the core Archimedes model was expanded to include data on rosuvastatin 20 mg/d and 40 mg/d doses from the JUPITER and STELLAR trials, and data on atorvastatin 40 mg/d and 80 mg/d from the CARDS, ASCOT-LLA, STELLAR, and TNT trials. 2003;19:689-698. This subgroup analysis of the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial examines the effects of statin therapy in hypercholesterolemic women. J Am Coll Cardiol 2019;73:e285-350 ⚫ Aims ⚫ To compare the long-term efficacy and safety between the rosuvastatin and atorvastatin treatment in patients Jun 1, 2005 · Clinical data were provided by the STELLAR trial, which is described in detail elsewhere. Setting 12 hospitals in South Korea, September 2016 to November 2019. Oct 18, 2023 · Objective To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. 2003;92(2):152-160. Similarly, rosuvastatin 40 mg reduces MI more than atorvastatin Jan 1, 2003 · The STELLAR study found that atorvastatin at doses between 10 and 80 mg had the highest number of treatment discontinuations due to AEs, followed by rosuvastatin, simvastatin, and pravastatin Mar 19, 2008 · These results are consistent with the STELLAR trial where rosuvastatin, atorvastatin, and simvastatin reduced LDL levels by 45. 6-week trial was to compare the LDL cholesterol reducing efficacy of the dose range of rosuvastatin with that of the Food and Drug Administration ap-proved dose ranges of all 3 of the most widely pre-scribed statins: atorvastatin, simvastatin, and pravasta-tin. Learn new and interesting things. The results of the Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). 897, 0. Rosuvastatin 10 to 40 mg was more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin. When diet and exercise alone are not enough, CRESTOR is prescribed along with diet in adults to lower high cholesterol and to slow plaque buildup in arteries as part of a treatment plan to lower cholesterol to goal. The STELLAR study was a 6-week randomized open-label trial that compared the efficacy of rosuvastatin, atorvastatin, simvastatin, and pravastatin in 2268 adults with primary hypercholesterolemia. Aug 21, 2003 · FIGURE 1 Low-density lipoprotein cholesterol (LDL-C) reductions with rosuvastatin 10 to 40 mg, atorvastatin 10 to 80 mg, simvastatin 10 to 80 mg, and pravastatin 10 to 40 mg at 6 weeks in the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial. Physicians have prescribed CRESTOR® (rosuvastatin) over 15 million times – ask if it’s right for you. O'donnell , and Peter Jones View all authors and affiliations Jan 15, 2016 · The Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial (clinicaltrials. Rosuvastatin 5 mg (n Sep 1, 2004 · CONCLUSION In the STELLAR trial, rosuvastatin 10 to 40 mg was more efficacious in improving the overall lipid pro- file, non-HDL-C, apolipoproteins, and lipid ratios in patients with hypercholesterolemia than milligram- equivalent doses of atorvastatin and milligram- equivalent or higher doses of simvastatin and pravastatin. It aims to evaluate the effectiveness of Jun 1, 2005 · Clinical trials have demonstrated that rosuvastatin is more efficacious than milligram-equivalent doses of atorvastatin at lowering LDL cholesterol levels and allowing patients to reach guideline goals. The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. However, healthcare providers and Doses (STELLAR* Trial) open-label, randomized,multicenter trial was to com-pare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low- ^ Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Patients were randomized to receive 1 of the 15 treatment options once-daily: Rosuvastatin 10, 20, 40 or 80 mg; Atorvastatin 10, 20, 40 or 80 mg; Simvastatin 10, 20, 40 or 80 mg and Pravastatin 10, 20 or 40 mg. 7%), (B) rosuvastatin versus simvastatin, and (C Nov 15, 2021 · Rosuvastatin is fully funded in New Zealand from 1 December 2021, subject to Special Authority criteria. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of To perform these virtual clinical trials, the core Archimedes model was expanded to include data on rosuvastatin 20 mg/d and 40 mg/d doses from the JUPITER and STELLAR trials, and data on atorvastatin 40 mg/d and 80 mg/d from the CARDS, ASCOT-LLA, STELLAR, and TNT trials. Drug costs were based on wholesale acquisition costs. STELLAR Study Group. However, healthcare providers and authorities require informati FIGURE 2. The study found that rosuvastatin produced greater reductions in LDL-C compared to equivalent and higher doses of other statins. 7 mmol/L [130 and In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor*) was compared with that of atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol§) for lowering plasma low-density lipoprotein cho Nov 29, 2007 · A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or Feb 1, 2005 · In terms of patients achieving goal, rosuvastatin 10 mg dominated (was more effective at equal or lower cost) atorvastatin 10 and 20 mg, pravastatin 20 and 40 mg, branded simvastatin 10-80 mg and generic simvastatin 40 and 80 mg. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. 2003 Jul 15;92(2):152-60. Peter H Jones, MD, Michael H Davidson, MD, Evan A Stein, MD, PhD, Harold E Bays, MD, James M McKenney, PharmD, Elinor Miller, MD, Valerie A Cain, MS, James W Blasetto, MD, MPH. nejm. 32. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). 14-18 Patients who participated in these studies had baseline LDL-cholesterol levels that ranged from 160-250 mg/dl. Pairwise comparisons were performed with rosuvastatin ^ Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Nov 16, 2024 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to the Rosuvastatin (STELLAR) trial , the efficacy of rosuvastatin, atorvastatin, simvastatin, and pravastatin was compared over 6 weeks of treatment, favoring rosuvastatin for LDL and TG lowering. " 2 days ago · Jones PH, Davidson MH, Stein EA, et al. ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP Jones PH, et al. 1 Any relevant practitioner, including nurse practitioners and pharmacist prescribers, can apply for a Special Authority. ^ CRESTOR ® (rosuvastatin) [prescribing information]. Least-squares mean (SE) percentage changes from baseline in HDL cholesterol at week 6 across dose ranges, and mean differences (SE) from analysis of variance (versus atorvastatin) or covariance (versus simvastatin and pravastatin) for (A) rosuvastatin versus atorvastatin for equivalent doses (the difference across the dose range for the rosuvastatin vs atorvastatin comparison could compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor*) was compared with that of atorvastatin (Lipitor†), simvastatin (Zocor‡), and pravastatin (Pravachol§) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of treatment. Background Rosuvastatin calcium (CRESTORQ{J) has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C). This 6-week, randomized, open-label trial (4522US/0002) was conducted from March 2002 to December 2003 at 76 academic and clinical research centers in the United States. Adapted from the ECLIPSE trial , . In this multicenter, parallel-group, open View Stellar Trial On Rosuvastatin PPTs online, safely and virus-free! Many are downloadable. 002 vs atorvastatin 20 mg, 40 mg, 80 mg; simvastatin 40 mg; and pravastatin 20 mg, 40 mg). 14 Strandberg et al 15 demonstrated LDL-C level changes over a 12-week trial, showing –46. amjcard. CLINTHERA. 2003). Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. Conclusion In summary, 10 mg of rosuvastatin tablet was comparable to 10 mg of atorvastatin tablet and more efficacious than 10 mg tablet simvastatin in reducing LDL levels after 12 Ridker P. 1%, on simvastatin (80 A atorvastatin; P pravastatin; R rosuvastatin; S simvastatin. Notable amongst these is the landmark statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR) trial done on 2431 patients comparing rosuvastatin with atorvastatin, simvastatin, and pravastatin Thus, in the DISCOVERY-Beta Study as in the earlier published MERCURY I (Schuster et al 2004), STELLAR (Jones et al 2003), and Rosuvastatin Study Group trials (Brown et al 2002), rosuvastatin was more effective than other statins used (atorvastatin, simvastatin, pravastatin) in decreasing LDL-C levels and allowing more patients to achieve the The STELLAR study29 was a 6-week, open-label, randomized, multicenter trial comparing rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of LDL cholesterol, changes in other lipid parameters, and achievement of NCEP-ATP III LDL-cholesterol goals. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) . Cost effectiveness was assessed with the net monetary benefit approach and a 1-year time horizon. . Notable amongst these is the landmark statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR) trial done on 2431 patients comparing rosuvastatin with atorvastatin, simvastatin, and pravastatin Mar 28, 2007 · Jones PH, Davidson MH, Stein EA. The STELLAR trial (with rosuvastatin in the range of 10-80 mg vs atorvastatin 10-80 mg, simvastatin 10-80 mg and pravastatin 10-40 mg in 2431 patients) demonstrated that the mean proportional reduction achieved with rosuvastatin at various doses was greater than the one obtained with comparators. The primary endpoints of these investigations were the difference in the percent Measurements and main results: In the STELLAR trial, doses of rosuvastatin produced reductions in LDL significantly greater than those of equivalent milligram/milligram doses of atorvastatin, simvastatin, or pravastatin. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C ‡160 and <250mg/dL) and triglycerides <400mg/dL were randomized to rosuvastatin 10–40mg, atorvastatin By studying the role of Rosuvastatin in the Stellar Study, researchers aim to further establish its efficacy and safety in managing cholesterol levels and preventing cardiovascular events. 888, and 0. 2005. Aug 1, 2003 · [Show full abstract] trials); and (3) to summarize overall efficacy and subset analyses of rosuvastatin data from all 5 trials. Jul 1, 2003 · The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. Get your numbers down with CRESTOR. Cerivastatin was also initially included in the study; however, this comparative arm was terminated when cerivastatin was discontinued. Eur Heart J 2020;41:111-188 Grundy SM, et al. J. Across dose ranges, rosuvastatin reduced total cholesterol significantly more than all comparators and triglycerides significantly more (p <0. Despite this, current LDL-C control is scarce, even Clinical trials have showed that rosuvastatin is an effective cholesterol-lowering medication, but it is also important to assess its cost-effectiveness. gov identifier: NCT00654537) compared rosuvastatin treatment with three other widely used statins (atorvastatin, simvastatin, and pravastatin) in a hypercholesterolemic patient population. Methods: In this randomized, multicenter, parallel-group, open-label trial (4522IL/0065), patients >18 years of age received rosuvastatin 10, 20, 40, or 80 mg; atorvastatin 10, 20, 40, or 80 mg; simvastatin 10, 20, 40, or The purpose was (1) to compare rosuvastatin 5 and 10 mg with atorvastatin 10 mg (data from 3 of the 5 trials); (2) to compare rosuvastatin 5 and 10 mg with simvastatin 20 mg and pravastatin 20 mg (data from 2 of the 5 trials); and (3) to summarize overall efficacy and subset analyses of rosuvastatin data from all 5 trials. 8 Patients on rosuvastatin 40 mg/day achieved up to 55% of LDL cholesterol reduction, on maximal dose of atorvastatin (80 mg/day) 51. ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP Mar 30, 2014 · This superiority of rosuvastatin is in keeping with the findings of several other trials done on other racial groups. 3%, respectively. et al. The primary endpoint was percentage change in LDL-C levels at … New data for CRESTOR® from stellar trial presented at ACC annual scientific session CRESTOR lowered LDL cholesterol by 46% to 55% at 10-40mg Peer-Reviewed Publication. , MacFadyen J. 2004. Coll. 9,10 The 4S study was the first study conclusively linking a statin with improved outcomes in patients with coronary heart disease. ⚫ Statins in coronary artery disease Background Mach F, et al. Nov 27, 2015 · Results . ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in 1036 patients with hypercholesterolemia and CHD, 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis. 152 - 160 View PDF View article View in Scopus Google Scholar The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C >-160 mg/dL and <250 mg/dL and triglycerides <400 Jul 6, 2012 · The STELLAR trial found that rosuvastatin 20 mg provided a significantly greater reduction in TC/HDL than atorvastatin 40 mg (p-value < 0. J. Secondary objectives included comparing rosuvastatin with comparators for other lipid modifications and achievement of National Cholesterol Nov 11, 2003 · The primary objective of the JUPITER trial is to determine whether long-term treatment with rosuvastatin (20 mg orally per day) will reduce the rate of first major cardiovascular events, defined as the combined end point of cardiovascular death, stroke, myocardial infarction, hospitalization for unstable angina, or arterial revascularization Jan 1, 2003 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of treatment. 7 to 45. Feb 1, 2012 · The lipid lowering arms of Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed the benefit of statin therapy in primary prevention of cardiovascular events. 3% [108]. Nov 20, 2008 · The trial was stopped after a median follow-up of 1. 5% with CRESTOR 20 mg (P value is less than . - "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Research Design. Nov 27, 2009 · Early rosuvastatin efficacy trials. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through December 2012 using Web-based search engines (PubMed and OVID Sep 1, 2004 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, rosuvastatin was noted to lower apoB levels by 36. Background: The safety and tolerability of rosuvastatin were assessed using data from 16,876patients who received rosuvastatin 5–40 mg in a multinational phase II/III/ IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. The cost-effectiveness of rosuvastatin 10-40 mg was compared with atorvastatin 10-80 mg, pravastatin 10-40 mg and both branded and generic simvastatin 10-80 mg in In the STELLAR trial, CRESTOR increased HDL-C at each dose. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. ^ Data on File, REF-148955, AstraZeneca Pharmaceuticals LP Jul 1, 2022 · In view of the lack of head-to-head trials comparing atorvastatin and rosuvastatin in terms of CV secondary prevention benefit and lack of real-world evidence of the effectiveness of rosuvastatin in patients post-ACS, we conducted a retrospective observational study aimed to compare the effectiveness and safety of the 2 high-intensity statin therapies (rosuvastatin vs atorvastatin) in patients Oct 1, 2009 · The Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial findings also support that rosuvastatin is more efficacious than milligram-equivalent doses of other statins in both lowering LDL-C levels and in enabling patients to achieve NCEP ATP III LDL-C goals. This study compared the efficacy and safety of low doses of rosuvastatin (10 mg) and atorvastatin (20 mg) in high-risk patients with hypercholesterolemia. Rosuvastatin 5 mg (n = 390) and 10 mg (n = 389) reduced low-density Sep 22, 2008 · SUMMARY. Curr Med Res Opin. [ Adapted from the METEOR trial, . Jul 15, 2003 · This multicenter trial, which is the largest trial of its kind to date comparing the lipid-modifying efficacy of statins, showed the greater efficacy of rosuvastatin in reducing LDL cholesterol, compared with atorvastatin, simvastatin, and pravastatin across dose ranges. Numbers listed with the drugs represent the drug doses (in milligrams). May 1, 2012 · Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol , 92 ( 2003 ) , pp. 1,4,12–16 STELLAR compared the efficacy of rosuvastatin with that of the most commonly used statins in the largest and most comprehensive The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C >-160 mg/dL and <250 mg/dL and triglycerides <400 Jun 1, 2005 · Clinical data were obtained from the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial. AstraZeneca. Methods A total of 996 patients with hypercholesterolemia (LDL-C ≥ 3. Am. 01. At 6 weeks, CRESTOR demonstrated significant HDL-C increases. All participants gave informed consent before any trial procedure was initiated. The annual acquisition cost/percentage LDL reduction was lower with rosuvastatin at doses of 10 mg (20. Intensive Statin Regimens and Coronary Disease n engl j med 365;22 nejm. 2003; 92(2):152–60. 006 Corpus ID: 19954130; Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. 15 The results of the Thus, in the DISCOVERY-Beta Study as in the earlier published MERCURY I (Schuster et al 2004), STELLAR (Jones et al 2003), and Rosuvastatin Study Group trials (Brown et al 2002), rosuvastatin was more effective than other statins used (atorvastatin, simvastatin, pravastatin) in decreasing LDL-C levels and allowing more patients to achieve the to Rosuvastatin (STELLAR) trial examines the effects of statin therapy in hypercholesterolemic women. 0). 92 dollars), 20 mg (18 May 20, 2019 · A Trial Safety Committee (TSC), with an independent chair, will provide overall supervision for the STELLAR trial and retain ultimate responsibility for the continuation of the trial. Methods: An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005 The STELLAR trial evaluated the effect of different doses of rosuvastatin (10–20 and 40 mg/day), atorvastatin, simvastatin (10, 20, 40 or 80 mg/day), and pravastatin (10, 20 or 40 mg/day). 2003;19(8):689-698. 2003;92:152-60. In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol) for lowering plasma low-density lipoprotein chole … Jul 15, 2003 · This multicenter trial, which is the largest trial of its kind to date comparing the lipid-modifying efficacy of statins, showed the greater efficacy of rosuvastatin in reducing LDL cholesterol, compared with atorvastatin, simvastatin, and pravastatin across dose ranges. 4 and < 5. The primary end point was percentage change from baseline in LDL-C at Week 6. Hypercholesterolemia is not only a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis. Dec 21, 2006 · Background Many patients at high risk of cardiovascular disease do not achieve recommended low-density lipoprotein cholesterol (LDL-C) goals. Methods Trial design. M. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024. obws hwnt sffixal lpsaw bnjlrt gcklg cjbf mykbkt dlaitzj dshes